In navigating Symbiopharm’s strategic shift, we adhered to a multi-pronged approach that emphasized innovation, market research, and consumer-centric brand development.
Our initial step involved a thorough assessment of Symbiopharm’s internal strengths and challenges in the B2B sector. This analysis laid the groundwork for understanding how these factors could be leveraged or addressed in the B2C transition.
Subsequently, we conducted extensive research to understand consumer needs and expectations in the gut health market. This included analyzing consumer behaviour, preferences, and gaps in the current market offerings.This was supplemented by a deep dive into the semiotics of the category. Enabling us to identify the most promising areas for brand and product development. This step was crucial in ensuring that the new brand resonated with consumers and stood out in the competitive pharmaceutical landscape.
The culmination of these efforts resulted in a comprehensive brand strategy and product portfolio for launch. This strategy not only defined a clear consumer target but also encompassed a holistic brand positioning, including naming, visual identity, and product pipeline planning. Integral to this phase was our close collaboration with Symbiopharm’s go-to-market partner, ensuring the strategy was primed for effective implementation.